Background
==========

As the most common form of dementia, Alzheimer's disease (AD) is predicted to affect 11.8% of all people globally by 2050 \[[@b1-medscimonit-23-2721]\]. Alzheimer's disease is a fatal neurodegenerative disorder which can be divided into early onset familial AD (EOAD) and late onset Alzheimer's disease (LOAD) \[[@b2-medscimonit-23-2721]\]. More than 98% of AD cases are LOAD, which are "sporadic" with no apparent familial recurrence of the disease and typically appears in older individuals (age 65 years and over \[[@b3-medscimonit-23-2721]\]. It is characterized by progressive neuronal degeneration, pathology of amyloid-b (Ab) deposition (senile plaques, SP), and loss of synapses and formation of neurofibrillary tangles (NFTs) that consist mainly of filaments of hyper-phosphorylated tau \[[@b4-medscimonit-23-2721]\].

The Ab precursor protein (APP), apolipoprotein E (APOE), and cleavage of APP by b-secretase or b-site APP cleaving enzyme 1 (BACE1) are indicated to be associated with AD \[[@b5-medscimonit-23-2721],[@b6-medscimonit-23-2721]\], and APOE4 (E4 allele of apolipoprotein E) is the only verified genetic risk factor for late- onset AD \[[@b4-medscimonit-23-2721],[@b7-medscimonit-23-2721]\].

miRNAs are a class of small non-coding RNAs of 20--22 nucleotides in length, which regulates more than 60% of protein-coding genes \[[@b8-medscimonit-23-2721]\] and miRNAs are associated with many neurodegenerative diseases, such as AD \[[@b9-medscimonit-23-2721]\]. Consequently, the research on miRNAs function and the exploration of miRNA replacement therapy is rapidly growing. Researchers have used microarray or high-throughput sequencing technology to detect mRNA and miRNA expression in AD. At present, autopsy is still necessary to diagnose AD accurately \[[@b10-medscimonit-23-2721]\]. In addition, there is no curative therapy for AD and the current drugs only have limited efficacies \[[@b4-medscimonit-23-2721]\]. Therefore, identifying non-invasive, accurate, early, and reliable biomarkers is essential for diagnosis and treatment for AD. In this study, through integrated analysis, we aimed to obtain more accurate results than possible with individual study. Functional annotation of DEGs and AD-specific miRNA-target gene network was performed, seeking to identify key DEGs and DEmiRNAs in AD to discover new diagnostic biomarkers for AD.

Material and Methods
====================

Microarray expression profiling in GEO
--------------------------------------

The Gene Expression Omnibus (GEO) is the largest database of high-throughput gene expression data, developed and maintained by the National Center for Biotechnology Information. The microarray datasets of AD were obtained from the GEO database (*<http://www.ncbi.nlm.nih.gov/geo>*). Microarray datasets in blood of AD patients and normal control (NC) group were selected and data with drug stimulation or transfection were excluded. The miRNA datasets were derived from the microarray experiments by Petra-Leidinger et al.

Data analysis
-------------

The raw data was preprocessed with background correction. We performed the normalization using the Linear Models for Microarray Data (Limma) package in R. Two-tailed Student's t-test was used to calculate individual P-values, and the Stouffer test was used to merge individual P-values. Multiple comparison correction was performed by Benjamini & Hochberg method to obtain FDR. We finally identified the DEGs with selected criterion of FDR \<0.001.

miRNA-target prediction
-----------------------

We used 6 bioinformatic algorithms (RNA22, miRanda, miRDB, miRWalk, PICTAR2, and TargetScan) to predict the putative target genes of differentially expressed miRNAs (DEmiRNAs). The threshold for the targets of DEmiRNAs was those genes predicted by ≥4 algorithms. Moreover, verified target genes of DEmiRNAs were obtained by the online tools of miRWalk (*<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>*). MiRNAs down-regulated the expression of its target genes in post-transcription, and the target genes whose expressions were inversely correlated with corresponding miRNAs were selected as miRNA targets with high accuracy based on the obtained gene expression data. Using Cytoscape software (*<http://www.cytoscape.org/>*), the miRNA-target gene interaction networks were constructed.

Functional annotation
---------------------

To analyze the function and the potential pathway of miRNA-target genes, functional annotation including Gene Ontology (GO) classification (molecular functions, biological processes and cellular component) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was performed by using the online software GeneCodis (*<http://genecodis.cnb.csic.es/analysis>*). FDR\<0.05 was defined as statistical significance.

QRT-PCR confirmation
--------------------

The 6 blood samples were collected from 3 normal control subjects and 3 patients who were diagnosed as having AD. Informed written consent was obtained from all participants, and research protocols were approved by the Ethics Committee of our hospital.

Total RNA was extracted with Trizol reagent (Invitrogen, China). cDNA was generated immediately from 1 μg extracted RNA by using SuperScript^®^ III Reverse Transcriptase (Invitrogen, China). With Power SYBR^®^ Green PCR Master Mix (Applied Biosystems, USA), quantitative PCR was performed by using an ABI 7500 real-time PCR system. The miScript II RT Kit was used to obtain the reverse transcriptions of miRNAs, and the miScript SYBR Green PCR Kit (Qiagen, Germany) was used to perform quantitative PCR. Relative gene expression was analyzed using 2^−DDCt^ method. The human 18srRNA and U6 were used as endogenous controls for mRNA and miRNA expression in analysis.

Results
=======

Differential expression analysis of genes in AD
-----------------------------------------------

Three gene expression datasets (GSE63060, GSE63061, GSE18309) and 1 miRNA expression dataset (GSE46579) was enrolled in this study ([Table 1](#t1-medscimonit-23-2721){ref-type="table"}). Twelve DEmiRNAs between the AD and NC groups used in our study were created by Petra-Leidinger et al. \[[@b11-medscimonit-23-2721]\] ([Table 2](#t2-medscimonit-23-2721){ref-type="table"}). The panel included 5 down-regulated and 7 up-regulated miRNAs. By integrated analysis (FDR \<0.001), 1759 genes displayed altered expression between AD and NC group, with 847 up-regulated genes and 912 down-regulated genes. The top 100 significantly up-regulated or down-regulated genes in AD compared to normal controls are displayed in a heat-map ([Figure 1](#f1-medscimonit-23-2721){ref-type="fig"}).

AD-specific DEmiRNA-target interaction network
----------------------------------------------

In total, 784 miRNA-mRNA interaction pairs were obtained, in which 578 miRNA-mRNA pairs included 159 up-regulated miRNA-mRNA pairs and 419 down-regulated miRNA-mRNA pairs were predicted by more than 4 algorithms. Additionally, 37 up-regulated miRNA-mRNA pairs and 169 down-regulated miRNA-mRNA pairs were verified by experiments. The miRNA-mRNA regulatory network was constructed based on these miRNA-mRNA interaction pairs, which consisted of 10 miRNAs (miR-26b-5p, miR-103a-3p, miR-107, miR-26a-5p, let-7f-5p, miR-532-5p, miR-151a-3p, miR-5010-3p, miR-1285-5p, let-7d-3p) and 695 targets differently expressed ([Figure 2](#f2-medscimonit-23-2721){ref-type="fig"}). MiR-26b-5p (degree=107), miR-103a-3p (degree=88), miR-107 (degree=88) and miR-26a-5p (degree=80) were the top 4 DEmiRNAs covering most DEGs.

Functional annotation
---------------------

After GO enrichment analysis (FDR \<0.05, [Table 3](#t3-medscimonit-23-2721){ref-type="table"}), the miRNA targets were significantly enriched in regulation of transcription (FDR=7.38E-05), interspecies interaction between organisms (FDR=0.000270215), protein binding (FDR=2.14E-26), and metal ion binding (FDR=2.50E-09). According to the KEGG pathway enrichment analysis (FDR \<0.05), several pathways were significantly enriched, including the insulin signaling pathway (FDR=0.0262808), lysosome (FDR=0.0441909), Huntington's disease (FDR=0.0247485, [Figure 3](#f3-medscimonit-23-2721){ref-type="fig"}), and basal transcription factors (FDR=0.0216603, [Table 4](#t4-medscimonit-23-2721){ref-type="table"}). In addition, we found 36 DEGs that were associated with Alzheimer's disease-related metabolic pathways ([Table 5](#t5-medscimonit-23-2721){ref-type="table"}), among of which 4 genes including low-density lipoprotein receptor-related protein 1 (LRP1), phospholipase C beta 2 (PLCβ2), NDUFA4, and Cyclin-dependent kinase activator (CDK5R1) were also the targets of DEmiRNAs ([Figure 4](#f4-medscimonit-23-2721){ref-type="fig"}).

QRT-PCR confirmation
--------------------

To verify the expression of integrated analysis, we selected 4 DEmiRNAs (miR-26b-5p, miR-26a-5p, miR-107, and miR-103a-3p) and 5 targets LRP1, CDK5R1, PLCβ2, NDUFA4, and discs large MAGUK scaffold protein 4 (DLG4). Based on the qRT-PCR results, the expression of LRP1, CDK5R1, and NDUFA4 were down-regulated, while the other 5 were up-regulated in AD compared to NC. The expression of miR-26b-5p, miR-26a-5p, LRP1, and CDK5R1 was inconsistent with results of our integrated analysis ([Figure 5](#f5-medscimonit-23-2721){ref-type="fig"}).

Discussion
==========

As the principal cognitive problem in humans, the incidence rate of AD increased significantly with the aging population. Since there is no cure for it, finding novel strategies of treatment for AD has long been a central goal. In this study, we performed miRNA and mRNA integrated analysis (MMIA), and obtained 1759 DEGs and 12 DEmiRNAs in blood of AD patients compared to NC. According to the functional annotation and AD-specific DEmiRNA-target interaction network, 5 DEGs (LRP1, PLCβ2, NDUFA4, CDK5R1, and DLG4) upon the regulation of 4 DEmiRNAs (miR-26b-5p, miR-26a-5p, miR-107, and miR-103a-3p) were associated with AD.

Neuritic plaques (NP) and neurofibrillary tangles (NFT) in the brain are 2 major hallmarks of AD \[[@b12-medscimonit-23-2721]\]. LRP1 is an APOE receptor in the brain. APOE can regulate the free cholesterol levels of neurons via LRP1, thereby mediating the APOE4 effect of NFT formation. Additionally, altered cholesterol metabolism significantly contributes to neuronal damage and to progression of AD. Hence, LRP1 may play a key role in the pathogenesis of AD by regulating cholesterol metabolism and NFT formation. Up-regulated LRP1 has been found in neurons in the hippocampus of AD patients \[[@b13-medscimonit-23-2721],[@b14-medscimonit-23-2721]\]. According to our integrated analysis, LRP1 was up-regulated in the blood of AD patients. However, LRP1 was down-regulated in blood of patients with AD in our q-RT-PCR expression confirmation. The precise role of LRP1 in AD needs further research.

CDK5R1 encodes p35s, which is necessary for activation of CDK5. P35s can be cleaved into its more stable and truncated form, termed p25, and increased production of p25 enhances the activity of CDK5 \[[@b15-medscimonit-23-2721]\]. With abnormal hyperphosphorylation of tau by activated CDK5, the numbers of NFTs which mainly composed of hyperphosphorylated microtubule associated protein tau was increased. Thus, the up-regulated CDK5R1 may increase the risk of AD by elevating the activation of CDK5, hyperphosphorylation of tau, and the formation of NFTs \[[@b16-medscimonit-23-2721]\]. In our study, CDK5R1 was up-regulated in AD, which was shown to have the same pattern in a previous study \[[@b17-medscimonit-23-2721]\]. In addition, increased p25 is associated with up-regulation of Ab and accumulation of intra-neuronal Ab, which are other major traits of AD \[[@b18-medscimonit-23-2721]\].

NDUFA4 encodes a protein in the respiratory chain of mitochondria \[[@b19-medscimonit-23-2721],[@b20-medscimonit-23-2721]\]. It has both NADH dehydrogenase activity and oxidoreductase activity \[[@b21-medscimonit-23-2721]\]. Deficiency of complex I was found in various tissues of patients with neurodegenerative diseases like AD and Parkinson's disease \[[@b22-medscimonit-23-2721]\]. In our study, NDUFA4 was down-regulated in AD, and it may be associated with the pathogenesis of AD via regulation in the respiratory chain of mitochondria.

DLG4 (also known as PSD95) is associated with anchoring glutamate receptors into the postsynaptic membrane \[[@b23-medscimonit-23-2721]\]. Abnormally expressed DLG4 presumably leads to disturbance of glutamatergic neurotransmission. In addition, DLG4 is involved in regulating amyloid-b deposition \[[@b23-medscimonit-23-2721]\]. Up-regulated DLG4 was detected in AD in our study, indicating its important role in AD, and up-regulated DLG4 might serve as a biomarker for AD.

Both extracellular and intracellular elevation of Ca2^+^ are associated with the neurodegeneration in AD \[[@b24-medscimonit-23-2721]\]. PLC (phosphoinositide-specific phospholipase C) is a major pathway activated by elevated intracellular calcium. As a member of the PLC family, PLCβ2 is activated by G proteins, and generates calcium signals in cells \[[@b25-medscimonit-23-2721]\]. In our study, PLCβ2 was up-regulated in AD, which may have an important role in the progression of AD. Based on this, we may be able to develop a new therapeutic strategy.

According to the KEGG enrichment analysis, NDUFA4, PLCβ2, and DLG4 were enriched in another neurodegenerative disorder, Huntington's disease, emphasizing the importance of these 3 genes in AD as well. Moreover, PLCβ2, CDK5R1, NDUFA4, and LRP1 were found to be enriched in the pathway of AD, which supports our findings.

Rod-like structures were found in AD patients, which consisted of actin and the actin-binding protein cofilin \[[@b26-medscimonit-23-2721]\]. Both miR103 and miR-107 have inhibitory effect on the translation of cofilin, so reduced miR103 and miR-107 may induce AD by exerting promotive effects on the level of protein cofilin and formation of rod-like structures. In addition, a correlation between NP counts, NFT counts, and decreased miR-107 expression was discovered \[[@b27-medscimonit-23-2721]\]. Down-regulated MiR-107 was detected in the temporal cortical gray matter of humans in the early progression of AD and down-regulated miR-103a-3p has been detected in AD \[[@b27-medscimonit-23-2721]\], which is consistent with our results in blood of AD patients. An AD-related gene, BACE1, is one of targets of both miR-107 and miR-103a-3p \[[@b28-medscimonit-23-2721]\]. Up-regulated BACE1 has been found in AD patients with down-regulation of miR-107 \[[@b28-medscimonit-23-2721],[@b29-medscimonit-23-2721]\]. MiR-107 and miR-103a-3p were 2 of top 4 DEmiRNAs covering most DEGs in AD, and BACE1, LRP1, CDK5R1, and DLG4 are all common targets of miR-107 and miR-103a-3p. Hence, we inferred that miR-107 and miR-103a-3p may play key roles in the progression of AD by regulating the expression of BACE1 and these 3 DEGs.

MiR-26a-5p and miR-26b-5p were the other 2 of top 4 DEmiRNAs covering most DEGs in AD. Our q-RT-PCR results showed that both miR-26a-5p and miR-26b-5p were up-regulated in AD. Previous studies also detected up-regulation of miR-26a-5p in AD by the NGS screening experiment \[[@b11-medscimonit-23-2721]\]. Dysregulation of miR-26a and miR-26b was found in the peripheral blood mononuclear cells of Parkinson's disease \[[@b30-medscimonit-23-2721]\] and AD patients \[[@b11-medscimonit-23-2721]\]. Additionally, NDUFA4 is one of targets of miR-26a-5p. Both CDK5R1 and DLG4 are targets of miR-26b-5p. Hence, we suspected that both miR-26a and miR-26b were mediators of AD. We concluded that miR-26a-5p and miR-26b-5p play roles in AD by regulating NDUFA4, CDK5R1, and DLG4. However, the expression of these 2 DEmiRNAs in AD in our integrated analysis was inconsistent with our q-RT-PCR results. Studies with larger sample sizes are needed.

Conclusions
===========

Our findings identified 5 DEGs (PLCβ2, CDK5R1, NDUFA4, DLG4, and LRP1) in blood of patients with AD compared to NC. Moreover, miR-107 and miR-103a-3p may play roles in the pathological process of AD by targeting LRP1, CDK5R1, and DLG4. MiR-26b-5p was also an up-regulator of AD by targeting CDK5R1 and DLG4. MiR-26a-5p was involved in AD by regulating NDUFA4. Thus, the DEmiRNAs and the corresponding targets obtained in our study will be potential biomarkers, and provide evidence for new strategies for design of drugs for AD treatment.
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###### 

mRNA and miRNA expression datasets used in this study.

  Data type   GEO ID     Platform                                                Samples (N: P)
  ----------- ---------- ------------------------------------------------------- ----------------
  mRNA        GSE63060   GPL6947 Illumina HumanHT-12 V3.0 expression beadchip    104: 145
  mRNA        GSE63061   GPL10558 Illumina HumanHT-12 V4.0 expression beadchip   134: 139
  mRNA        GSE18309   GPL570 Affymetrix Human Genome U133 Plus 2.0 Array      3: 3
  miRNA       GSE46579   GPL11154 Illumina HiSeq 2000 (Homo sapiens)             22: 48

###### 

Significantly enriched up- and down-regulated miRNA in AD \[[@b11-medscimonit-23-2721]\].

  miRNAs            Regulation   FDR        miRNAs            Regulation   FDR
  ----------------- ------------ ---------- ----------------- ------------ ----------
  hsa-miR-151a-3p   Up           7.29E-07   hsa-let-7d-3p     Up           0.000872
  brain-mir-112     Up           7.29E-07   hsa-let-7f-5p     Down         1.01E-05
  hsa-miR-1285-5p   Up           4.54E-06   hsa-miR-107       Down         0.000367
  hsa-miR-5010-3p   Up           8.15E-05   hsa-miR-103a-3p   Down         0.000437
  brain-mir-161     Up           0.003185   hsa-miR-532-5p    Down         0.015277
  hsa-miR-26a-5p    Up           0.003185   hsa-miR-26b-5p    Down         0.044145

###### 

Top 15 most significantly enriched GO terms in AD.

  GO ID                    GO Term                                                            Count   P-value       FDR
  ------------------------ ------------------------------------------------------------------ ------- ------------- -------------
  **Biological process**                                                                                            
   GO: 0006355             regulation of transcription, DNA-dependent (BP)                    42      6.75E-08      7.38E-05
   GO: 0044419             interspecies interaction between organisms (BP)                    16      4.94E-07      0.000270215
   GO: 0042981             regulation of apoptotic process (BP)                               12      2.07E-06      0.000754514
   GO: 0016192             vesicle-mediated transport (BP)                                    11      6.76E-06      0.0018482
   GO: 0006366             transcription from RNA polymerase II promoter (BP)                 13      1.66E-05      0.00302682
   GO: 0001889             liver development (BP)                                             7       1.45E-05      0.00316647
   GO: 0046580             negative regulation of Ras protein signal transduction (BP)        4       3.28E-05      0.00512894
   GO: 0008219             cell death (BP)                                                    9       4.40E-05      0.00600976
   GO: 0016573             histone acetylation (BP)                                           4       5.12E-05      0.00621195
   GO: 0035556             intracellular signal transduction (BP)                             12      0.000100293   0.00913503
   GO: 0016070             RNA metabolic process (BP)                                         11      9.84E-05      0.00978072
   GO: 0042493             response to drug (BP)                                              12      9.42E-05      0.0102999
   GO: 0006470             protein dephosphorylation (BP)                                     7       0.000126898   0.0106692
   GO: 0000209             protein polyubiquitination (BP)                                    7       0.000142801   0.0111487
   GO: 0015939             pantothenate metabolic process (BP)                                3       0.000179128   0.0130525
  **Molecular function**                                                                                            
   GO: 0005515             protein binding (MF)                                               130     4.93E-29      2.14E-26
   GO: 0046872             metal ion binding (MF)                                             71      1.15E-11      2.50E-09
   GO: 0000166             nucleotide binding (MF)                                            53      4.56E-09      6.59E-07
   GO: 0003700             sequence-specific DNA binding transcription factor activity (MF)   28      3.96E-07      4.30E-05
   GO: 0008270             zinc ion binding (MF)                                              45      6.18E-07      5.37E-05
   GO: 0003677             DNA binding (MF)                                                   42      1.05E-06      7.63E-05
   GO: 0016740             transferase activity (MF)                                          20      1.04E-05      0.000646436
   GO: 0005524             ATP binding (MF)                                                   34      2.21E-05      0.00119919
   GO: 0005509             calcium ion binding (MF)                                           20      2.91E-05      0.00140122
   GO: 0001948             glycoprotein binding (MF)                                          5       6.10E-05      0.00264899
   GO: 0008134             transcription factor binding (MF)                                  11      0.000128895   0.00372935
   GO: 0004402             histone acetyltransferase activity (MF)                            5       9.73E-05      0.00383997
   GO: 0003723             RNA binding (MF)                                                   18      0.000126578   0.00392391
   GO: 0016787             hydrolase activity (MF)                                            24      0.000114083   0.00412599
   GO: 0003713             transcription coactivator activity (MF)                            10      0.00012437    0.00415205
  **Cellular component**                                                                                            
   GO: 0005737             cytoplasm (CC)                                                     130     5.21E-22      1.37E-19
   GO: 0005634             nucleus (CC)                                                       130     5.23E-21      6.88E-19
   GO: 0005739             mitochondrion (CC)                                                 42      1.14E-09      7.49E-08
   GO: 0005622             intracellular (CC)                                                 52      9.02E-10      7.91E-08
   GO: 0005829             cytosol (CC)                                                       54      2.55E-09      1.34E-07
   GO: 0016020             membrane (CC)                                                      81      9.40E-09      4.12E-07
   GO: 0005654             nucleoplasm (CC)                                                   28      3.39E-07      1.11E-05
   GO: 0005730             nucleolus (CC)                                                     38      3.27E-07      1.23E-05
   GO: 0000139             Golgi membrane (CC)                                                15      4.59E-05      0.00134136
   GO: 0005624             membrane fraction (CC)                                             16      0.00015706    0.00413068
   GO: 0005783             endoplasmic reticulum (CC)                                         24      0.000176871   0.00422883
   GO: 0005794             Golgi apparatus (CC)                                               23      0.000239488   0.00524877
   GO: 0008537             proteasome activator complex (CC)                                  2       0.000329029   0.00618105
   GO: 0031235             intrinsic to internal side of plasma membrane (CC)                 3       0.000305668   0.00618389
   GO: 0030529             ribonucleoprotein complex (CC)                                     7       0.000516178   0.00905032

###### 

Most significantly enriched KEGG pathways for differentially expressed target genes.

  KEGG ID    KEGG term                     Count   FDR         Genes
  ---------- ----------------------------- ------- ----------- ------------------------------------------------------------------------
  hsa04910   Insulinsignaling pathway      7       0.0262808   FOXO1, PTPN1, PHKA2, FLOT2, SOCS1, FASN, CBL
  hsa04142   Lysosome                      6       0.0441909   GGA3, TPP1, ATP6AP1, GNS, IGF2R, LAPTM5
  hsa05016   Huntington's disease          7       0.0247485   DLG4, PLCβ2, EP300, NDUFA4, SOD2, CREBBP, SP1
  hsa03022   Basal transcription factors   4       0.0216603   GTF2H5, GTF2A2, TAF12, TAF5
  hsa04010   MAPK signaling pathway        10      0.0366068   PPM1B, RASGRP3, CACNA1E, DUSP1, RELB, RASA2, SRF, MAPK8IP3, NF1, HSPA8
  hsa03040   Spliceosome                   7       0.0382035   SRSF6, RBM17, DHX16, NCBP1, NAA38, SRSF3, HSPA8

###### 

Differently expressed genes enriched in pathway of Alzheimer's disease.

  KEGG ID    KEGG term             Count   FDR        Genes
  ---------- --------------------- ------- ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa05010   Alzheimer's disease   36      1.38E-12   COX4I1, NDUFA8, ATP5J, NDUFAB1, ITPR3, COX7C, NDUFV2, ATP5F1, ATP5D, NDUFS4, COX6A1, FAS, LRP1, COX5B, PLCB2, ATP5H, NDUFB3, NAE1, NDUFA4, NCSTN, NDUFB6, UQCRC2, ATP5C1, NDUFA9, COX7A2, COX7B, UQCRB, NDUFA1, CDK5R1, NDUFB2, COX6C, ATP5O, NDUFB5, NDUFS3, UQCRH, UQCRQ
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